Strategies to Manage Antibody Drug Conjugates (ADC) - Related Toxicities in Breast Cancer - Episode 5
Navigating SG-related Diarrhea
Panelists discuss how to manage sacituzumab govitecan therapy, including absolute neutrophil count cutoffs for dose adjustments, handling febrile neutropenia, comparing diarrhea rates to clinical trials, identifying risk factors, and strategies for managing SG-related diarrhea.
Video content above is prompted by the following:
- Please comment on your absolute neutrophil count cutoff for dose reductions and/or delay of sacituzumab govitecan (SG) therapy.
- How do you manage subsequent doses for patients who experienced febrile neutropenia with the previous cycle?
- How often do you see diarrhea (associated with SG) in your clinical practice? How does it compare to the rates reported in clinical trials (ASCENT, TROPiCS-02)?
- Are there risk factors that can predict those who are at higher risk for developing diarrhea?
- Are there any situations where you would consider testing for UGT1A1*28 homozygosity?
- Please comment on how you typically manage SG-related diarrhea.
- Are you utilizing prophylactic atropine or loperamide to prevent cholinergic syndrome prior to Cycle 1 of SG?
- Please comment on your management strategy for SG-related diarrhea (any similarities vs differences).
Related Content:
